8-K: Acadia Pharmaceuticals Reports Strong 2024 Financial Results, Revenue Jumps 32%

Acadia Pharmaceuticals announces positive Q4 and full-year 2024 financial results, highlighted by a 32% increase in total net product sales and provides revenue guidance for 2025.

Summary

• Acadia Pharmaceuticals reported its financial results for the fourth quarter and full year ended December 31, 2024.
• Total revenues for 2024 were $957.8 million, a 32% increase compared to 2023.
• Fourth quarter DAYBUE net product sales reached $96.7 million, with full year sales at $348.4 million.
• NUPLAZID net product sales were $162.9 million for the fourth quarter and $609.4 million for the full year.
• The company anticipates total revenue between $1.03 and $1.095 billion for 2025.
• DAYBUE net sales are projected to be between $380 and $405 million in 2025.
• NUPLAZID net sales are expected to range from $650 to $690 million in 2025.
• A marketing authorization application for trofinetide was submitted to the European Medicines Agency (EMA) with expected approval in the first quarter of 2026.
• The last patient in the COMPASS PWS Phase 3 study of ACP-101 is expected to be enrolled in the fourth quarter of 2025, with topline results in the first half of 2026.
• The last patient in the RADIANT Phase 2 study of ACP-204 is expected to be enrolled in the first quarter of 2026, with topline results in mid-2026.
• Acadia plans to initiate a Phase 2 study of ACP-204 for Lewy Body Dementia Psychosis in the third quarter of 2025.
• Acadia closed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million before fees and expenses in December 2024.
• Thomas Andrew Garner was appointed as Chief Commercial Officer in December 2024.
• Acadia entered an exclusive worldwide license agreement with Saniona for ACP-711 in November 2024.
• Net income for the full year 2024 was $226.5 million, or $1.37 per common share, compared to a net loss of $61.3 million, or $0.37 per common share, for the same period in 2023.
• At December 31, 2024, Acadia's cash, cash equivalents, and investment securities totaled $756.0 million, compared to $438.9 million at December 31, 2023.

Sentiment

Score: 9

Explanation: The document presents a highly positive outlook with strong financial results, successful product performance, and promising pipeline developments. The company's guidance for 2025 further reinforces this positive sentiment.

Positives

• Acadia experienced a substantial 32% revenue growth in 2024, reaching $957.8 million.
• Both DAYBUE and NUPLAZID achieved record revenues in the fourth quarter of 2024.
• The company successfully sold its Rare Pediatric Disease Priority Review Voucher for $150 million.
• Acadia reported a net income of $226.5 million for 2024, a significant turnaround from the previous year's net loss.
• The company's cash position is strong, with $756.0 million in cash, cash equivalents, and investment securities.
• Acadia is expanding its DAYBUE field force in the US and building its EU commercial team.
• Acadia is advancing its later-stage pipeline programs toward key milestones.

Negatives

• Research and development expenses increased in Q4 2024 compared to the same period in 2023 ($100.7 million vs $66.7 million).
• Selling, general and administrative expenses also increased in Q4 2024 compared to the same period in 2023 ($130.1 million vs $111.5 million).

Risks

• The company's future performance depends on the successful commercialization of its products.
• Clinical trials may face risks of unsuccessful enrollment and negative or inconsistent results.
• Acadia relies on third-party collaborators, manufacturers, and suppliers.
• The company faces competition from other products and therapies.
• Acadia's ability to execute its business strategy depends on its ability to generate or obtain the necessary capital.

Future Outlook

Acadia anticipates total revenue between $1.03 and $1.095 billion for 2025, with NUPLAZID net sales ranging from $650 to $690 million and DAYBUE net sales between $380 and $405 million. The company also provided guidance for R&D and SG&A expenses.

Management Comments

• We closed 2024 on a strong note with each of our brands achieving record revenues in the fourth quarter and well-positioned for continued growth in 2025, said Catherine Owen Adams, Chief Executive Officer.
• To support this growth in 2025 we will continue investing in consumer activation to drive market share expansion for NUPLAZID in the US.
• We plan to expand our DAYBUE field force in the US and build our EU commercial team in anticipation of potentially launching trofinetide there next year.
• Beyond the growth of our commercial brands, our later-stage pipeline programs are advancing toward key milestones, including topline readouts starting in the first half of 2026, and our ongoing business development efforts continue to produce compelling opportunities like ACP-711 and other programs that we are excited to share more about at our inaugural R&D Day in June.

Industry Context

Acadia's focus on neuroscience and neuro-rare diseases positions it in a growing market with unmet needs. The company's success with NUPLAZID and DAYBUE demonstrates its ability to develop and commercialize innovative therapies. The expansion into Europe with trofinetide and the advancement of its pipeline programs could further solidify its position in the industry.

Comparison to Industry Standards

• Acadia's revenue growth of 32% significantly outpaces the average growth rate for established pharmaceutical companies, which typically ranges from 5-10%.
• Companies like Biogen and Novartis, which also focus on neurological disorders, have similar R&D spending as a percentage of revenue, but Acadia's smaller size allows for potentially greater impact from its pipeline.
• The $150 million sale of the PRV is comparable to other recent PRV sales in the rare pediatric disease space, indicating a fair market value for the asset.
• Acadia's cash position of $756 million provides a strong foundation for future growth and acquisitions, similar to companies like Neurocrine Biosciences which maintain a healthy cash balance for strategic investments.

Management Changes

Stakeholder Impact

• Shareholders will likely react positively to the strong financial results and positive outlook.
• Employees may benefit from the company's growth and expansion plans.
• Patients may gain access to new and improved therapies as the company's pipeline progresses.
• Suppliers and distributors may see increased business opportunities as the company's sales grow.
• Creditors may view the company as a lower-risk borrower due to its strong financial position.

Next Steps

• Continue investing in consumer activation to drive market share expansion for NUPLAZID in the US.
• Expand the DAYBUE field force in the US and build the EU commercial team.
• Advance later-stage pipeline programs toward key milestones.
• Initiate a Phase 2 study of ACP-204 for Lewy Body Dementia Psychosis in the third quarter of 2025.
• Announce topline results from the COMPASS PWS Phase 3 study of ACP-101 in the first half of 2026.
• Announce topline results from the RADIANT Phase 2 study of ACP-204 in mid-2026.
• Initiate a Phase 2 study of ACP-711 in essential tremor in 2026.

Key Dates